Positive and negative drug selection pressures on the N348I connection domain mutation; new insights from in vivo data. 18th International HIV Drug Resistance Workshop, June 2009.. 2009.
Predicting NNRTI resistance - do polymorphisms matter? 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.. 2011.
Predictors of death and response to therapy in patients with multi (three)-class drug resistant (MDR) HIV in the UK. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.. 2005.
Prevalence and patterns of antiretroviral drug resistance at low plasma HIV RNA load levels. 17th International HIV Drug Resistance Workshop, 10-14 June 2008.. 2008.
Prevalence and predictors of protease inhibitor (PI) mutations in HIV-infected UK adults treated with ritonavir-boosted lopinavir as their first PI. 17th Annual Conference of the British HIV Association, 6-8 April 2011.. 2011.
The Prevalence of Darunavir Associated Mutations in PI-naive and PI-experienced HIV-1 Infected Children in the UK. 17th Conference on Retroviruses and Opportunistic Infections, February 2010.. 2010.
The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK. Antivir Ther. 17:599-603.. 2012.
Prevalence of reduced drug susceptibility in treatment-naive patients in the UK. 13th International Drug Resistance Workshop, 8-12 June 2004.. 2004.
Probabalistic Estimation of HIV-1 Subtype B Transmission Rates from Viral Phylogenies. Conference on Retroviruses and Opportunistic Infections (CROI) 2016.. 2016.
Protease mutations emergining on darunavir in protease inhibitor-naive and experienced patients in the UK. International Congress of Drug Therapy in HIV Infection, November 2014.. 2014.
Rapid Increase in the Frequency of Wild Type HIV-1 Drug Resistance Reports among ART-experienced Patients: UK. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.. 2013.
Recent phylodynamics of the HIV epidemic among MSM in the UK. 15th Conference on Retroviruses and Opportunistic Infections, February 2008.. 2008.
Results of HIV-1 drug resistance tests performed in ART-experienced patients in the UK: patterns 2008 to 2015. BHIVA Spring.. 2018.
Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.. AIDS Res Ther. 15(1):11.. 2018.
Risk of development of drug resistance in patients starting antiretroviral therapy with three or more drugs in routine clinical practice. 13th International Drug Resistance Workshop, 8-12 June 2004.. 2004.
Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Antivir Ther. 18:213-9.. 2013.
Significant HIV-1 subtype differences observed in the development of accessory mutations associated with high-level resistance to reverse transcriptase inhibitors. International Workshop on HIV & Hepatitis Virus Resistance and Curative Strategies, 5-9 June 2012. Antiviral Therapy 17 Suppl 1:A84.. 2012.
Source of HIV-1 drug-resistant minority variants in people who are recently infected. 24th International HIV Dynamics and Evolution.. 2017.